Original title: CCTV financial comment on the sharp price cuts! How much is the future space for anticancer drugs?
In May 1st of this year, China announced that the tariff of imported anticancer drugs was reduced to zero. At the same time, 154 kinds of anticancer drugs, including imported drugs and domestic drugs, were tax reduced, and the value-added tax was reduced from 17% to 3%. Now, the implementation of the new policy is almost three months. What are the new changes in the price reduction of anticancer drugs? How to follow up the supporting mechanism? How much is the future space for reducing the price of anticancer drugs?
In July 30th, the CCTV financial review invited Wang Zhen, a researcher at the Institute of Economic Research of the Chinese Academy of Social Sciences, and the chief economist of the national development and Reform Commission International Cooperation Center, Wan Zhe, to explore the studio.
What are the new changes in the price reduction of anticancer drugs?
Measures and news about the price reduction of anticancer drugs have been continuous in recent months.
In April 12th, the Executive Council of the State Council decided to implement zero tariff on imported anticancer drugs from May 1st.
In June 20th, the Executive Council of the State Council urged the anti cancer drugs to speed up the price reduction so that the masses could have more sense of gain.
In July 8th, the national health insurance agency said that through the implementation of access negotiations and other measures to promote the reduction of anticancer drugs.
Reporters in the survey also found that in the 3 months, the price of anti-cancer drugs has fallen to varying degrees, and the cost of the individual's burden has fallen sharply.
Wang Zhen: lowering taxes has led to a fall in supply costs of anticancer drugs.
Wang Zhen, a researcher at the Institute of Economic Research of the Chinese Academy of Social Sciences: in fact, this combination, the first after the import of anti-cancer drugs, reduced the supply cost; the second medical insurance collectively negotiated to reduce the price of medicine into medical insurance, and the third patients were reimbursed after entering the medical insurance. There is also a significant reduction in patient pays. From the point of view of supply cost, from the point of view of purchasing, and from the point of view of the patient's own payment, the patient's burden has been significantly reduced.
Wan Zhe: the high price of the original anticancer drugs is a global problem.
National Development and Reform Commission International Cooperation Center Chief Economist Wan zhe: the cost of the global original research on anti-cancer drugs is relatively high, there is a anticancer drug called gleevin, the initial investment of up to about 5 billion dollars. It is conceivable that if the drug is developed and patented for 20 years, it will certainly have to be supported by a certain price, and then make further investment in research and development. Therefore, we can not expect the price reduction of the original anticancer drugs to be particularly high.
How to follow up the anti-cancer drug price matching mechanism?
Wang Zhen: perfecting the policy of drug proportion and promoting the application of home-made anti-cancer drugs
Wang Zhenzhen, a researcher at the Institute of Economics, Chinese Academy of Social Sciences, said: The proportion of drugs consumed by patients in the course of seeing a doctor is the proportion of the total expenses. In order to reduce the price of the drug and change the current situation of medicine and medicine, I think there should be a more flexible assessment method, which makes some homemade anti cancer drugs achieve the consistency evaluation effect and quality, which is similar to the original research effect, and the price is low, and it has entered the coverage of medical insurance, through reform. To make the common people benefit.
Wang Zhen: unswervingly push forward the reform of medical system and reform the deep-seated institutional obstacles.
Wang Zhen, a researcher at the Institute of Economic Research of the Chinese Academy of Social Sciences: to further promote the reform of the medical and health system, to remove some institutional mechanisms of the obstacles, let the common people enjoy the benefits, so that hospitals and doctors are willing to choose some anti cancer drugs for patients with good curative effect and reasonable price.
Wan Zhe: rational treatment of anticancer drugs into medical insurance
Wan Zhe, chief economist of the International Cooperation Center of the National Development and Reform Commission, said: For cancer patients, treatment time is also longer, and drugs are indeed more expensive. Of course, patients want to use drugs to enter health insurance, reimbursement range can be expanded. But in fact, we should rationally treat the problem of entering medical insurance with anticancer drugs, that is, to ensure the medical needs of more cancer patients, and to ensure that the overall medical security is stable and sustainable.
How big is the future space for reducing the price of anticancer drugs?
Yang Yan Sui, Professor of School of public administration, Tsinghua University, will further reduce the price of anticancer drugs in the future. On the one hand, we should strengthen the ability to negotiate the price of medical insurance and strengthen the supervision of drug use prudently; on the other hand, to speed up the research and development ability of domestic pharmaceutical enterprises, the original research enterprises should endure loneliness.
Jiao Hong, director of the State Administration for drug supervision and administration: for the overseas listed drugs that are in urgent need of clinical, anti AIDS and anti cancer, it will be included in the priority examination and approval channel to speed up the examination and approval. It is expected that these products will be reduced to the Chinese market for 1-2 years.
Click on the entry:
"I am not a drug God" has become popular at the high price of life-saving drugs.
Editor in responsibility: Huo Yuang
Waonews is a news media from China, with hundreds of translations, rolling updates China News, hoping to get the likes of foreign netizens